Lista de obras - Sara Pusceddu - Dominio Público Uruguay

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

artículo científico publicado en 2018

A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer ⬇️

artículo científico publicado el 23 de abril de 2011

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study

artículo científico publicado en 2014

Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis

artículo científico publicado en 2019

Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?

artículo científico publicado en 2020

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2007

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.

artículo científico publicado en 2011

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis

scientific article published on 05 April 2019

Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature.

artículo científico publicado en 2011

Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.

artículo científico publicado en 2017

Diagnosis and management of typical and atypical lung carcinoids

artículo científico publicado en 2016

Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.

artículo científico publicado en 2018

Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm

artículo científico publicado en 2019

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

artículo científico publicado en 2018

Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update

artículo científico publicado en 2017

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

artículo científico publicado en 2014

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

artículo científico publicado en 2017

Everolimus treatment in advanced solid tumors: a personal view

artículo científico publicado en 2015

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.

artículo científico

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

artículo científico publicado en 2016

Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors

artículo científico publicado en 2019

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)

scientific article published on 07 January 2019

Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

artículo científico publicado en 2016

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

scientific article published on 13 April 2018

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

artículo científico publicado en 2016

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms

artículo científico publicado en 2019

Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?

artículo científico publicado en 2013

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

artículo científico publicado en 2016

Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.

artículo científico publicado en 2016

Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.

artículo científico publicado en 2016

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

artículo científico publicado en 2017

Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors

artículo científico

Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.

artículo científico publicado en 2014

Real-world study of everolimus in advanced progressive neuroendocrine tumors

artículo científico publicado en 2014

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

artículo científico publicado en 2007

Safety profile and treatment response of everolimus in different solid tumors: an observational study

artículo científico publicado en 2014

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs

artículo científico publicado en 2019

Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum

artículo científico publicado en 2012

Sunitinib and everolimus in pancreatic neuroendocrine tumors

artículo científico publicado en 2012

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

artículo científico publicado en 2018

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives

scientific article published on 10 November 2018

The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories

artículo científico publicado en 2016

The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

artículo científico publicado en 2018

The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST

artículo científico publicado en 2018

The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence

scientific article published on 31 July 2020

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

artículo científico publicado en 2018

Treatment of lung large cell neuroendocrine carcinoma.

artículo científico publicado en 2016

Update on medical treatment of small intestinal neuroendocrine tumors

artículo científico publicado en 2016

Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities

artículo científico publicado en 2013

Lista de obras de Sara Pusceddu

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer ⬇️

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study

Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis

Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis

Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature.

Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.

Diagnosis and management of typical and atypical lung carcinoids

Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.

Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

Everolimus treatment in advanced solid tumors: a personal view

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer

From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)

Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms

Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.

Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.

Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors

Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.

Real-world study of everolimus in advanced progressive neuroendocrine tumors

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

Safety profile and treatment response of everolimus in different solid tumors: an observational study

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs

Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum

Sunitinib and everolimus in pancreatic neuroendocrine tumors

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives

The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories

The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST

The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Treatment of lung large cell neuroendocrine carcinoma.

Update on medical treatment of small intestinal neuroendocrine tumors

Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities